Conformationally constrained parathyroid hormone (pth) analogs
CA 2454275 C · Owner: Potts, John T. Jr. · Inventors: Potts, John T. Jr.; Gardella, Thomas J.; Shimizu, Naoto
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to conformationally constrained parathyroid hormone (PTH) analogs, and methods of preparing and using the PTH analogs. The invention provides novel PTH polypeptide derivatives containing amino acid substitutions at selected positions in the polypeptides. The invention provides derivatives of PTH (1-34), PTH(1-21) PTH(1-20), PTH(1-19), PTH(1-, 18), PTH(1-17) PTH(1-16), PTH(1-15), PTH(1-14), PTH(1-13) PTH(1-12), PTH(1-, 11) and PTH(1-1 0) polypeptides wherein at least one residue in each , polypeptide is a helix preferably an a-helix, stabilizing residue. The invention also provides methods of making such peptides. Further the , invention encompasses …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 19, 2002 and granted October 23, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 19, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 19, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.